Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-02-14

Clinical Trial Update: Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sirolimus in combination with Eylea versus Eylea alone for exudative age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EYLEA (Aflibercept)
  • Sirolimus (Sirolimus)

Snippet

Sponsor: Maturi, Raj K., M.D., P.C. | Conditions: Exudative Age Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2018-02-14